Lemborexant + Placebo

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sleep Initiation and Maintenance Disorders

Conditions

Sleep Initiation and Maintenance Disorders

Trial Timeline

Nov 6, 2020 → Mar 17, 2023

About Lemborexant + Placebo

Lemborexant + Placebo is a phase 3 stage product being developed by Eisai for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT04549168. Target conditions include Sleep Initiation and Maintenance Disorders.

What happened to similar drugs?

20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved

Approved (20) Terminated (2) Active (0)
Zolpidem MR + EstazolamAstellas PharmaApproved
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
Lemborexant + PlaceboEisaiApproved
Eszopiclone + Placebo controlSumitomo PharmaApproved
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
Lunesta + Placebo controlSumitomo PharmaApproved
LunestaSumitomo PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT07384429ApprovedRecruiting
NCT06874855ApprovedRecruiting
NCT04549168Phase 3Completed
NCT02952820Phase 3Completed

Competing Products

20 competing products in Sleep Initiation and Maintenance Disorders

See all competitors